LTR Secures First U.S. Commercial Agreement for ROXUS
Filed with ASX · · 4 pages · English
Summary by 6ix AI
LTR Pharma Limited has signed a binding term sheet with Shed Holdings LLC to commercialize ROXUS in the United States, marking a significant step in its U.S. market strategy. The agreement includes a performance-based minimum commercial volume target for ROXUS prescriptions during the first year after launch. This arrangement establishes the first commercial route-to-market for ROXUS in the U.S., leveraging Shed's telehealth platform for patient access.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from LTR Pharma
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN Phase II Clinical Study Completes Recruitment
- Appendix 4D and Half Yearly Report
- SPONTAN Shows Positive Outcomes in Younger Men with ED
Later from LTR Pharma
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- Response to ASX Aware Letter
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- LTR Executes U.S. Commercial Agreement with Strive
- SPONTAN Real-World Study Reports 93% Response
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma